Evidence map›Paper›PMID 32006298›Full record

ReviewMolecular diversity2021

Calix[4]API-s: fully functionalized calix[4]arene-based facial active pharmaceutical ingredients.

Fazel Nasuhi Pur

Abstract readReview
PubMed Publisher
In one paragraph

Review in Molecular diversity, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. RSC advances · 2021
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Fazel Nasuhi PurHealth Technology Incubation Center, Urmia University of Medical Sciences, Urmia, Iran. fazelnasuhi@gmail.com.ORCID http://orcid.org/0000-0002-3948-6912

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This mini-review covers 25 fully functionalized facial calix[4]arene-based symmetrical and conical cyclic tetramers with significant (comparable to established therapeutic agents) anticancer and anti-infective activities. The main role of the calixarene scaffold in these calix[4]arene-based active pharmaceutical ingredients (calix[4]API-s) is to replicate embedded phenolic units in the cyclic tetramers. So, probably owing to the multivalency, facial, conical structures of calix[4]API-s and synergistic effect of their four replicated units, they can be considered as effective bioactive agents.

Indexed as

Anti-Infective AgentsAntineoplastic AgentsCalixarenesPhenolsAnimalsHumansAnti-Infective AgentsAntineoplastic Agentscalix(4)areneCalixarenesPhenolsActive pharmaceutical ingredientAnticancerAnti-infectiveCalix[4]areneCyclic tetramer

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.